Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Short Interest Up 255.6% in December

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) was the target of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 175,300 shares, a growth of 255.6% from the December 15th total of 49,300 shares. Currently, 2.8% of the shares of the stock are sold short. Based on an average trading volume of 272,300 shares, the short-interest ratio is currently 0.6 days.

Protagenic Therapeutics Price Performance

NASDAQ:PTIX traded down $0.00 during trading hours on Tuesday, hitting $0.47. The stock had a trading volume of 183,480 shares, compared to its average volume of 185,735. The company has a 50 day simple moving average of $0.58 and a two-hundred day simple moving average of $0.64. The firm has a market capitalization of $3.35 million, a price-to-earnings ratio of -0.37 and a beta of 0.28. Protagenic Therapeutics has a one year low of $0.44 and a one year high of $1.87.

Protagenic Therapeutics Company Profile

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.